Genedrive PLC Publication of Circular and Notice of GM (2438X)
24 April 2023 - 8:54PM
UK Regulatory
TIDMGDR
RNS Number : 2438X
Genedrive PLC
24 April 2023
genedrive plc
("genedrive", the "Group" or the "Company")
Publication of Circular and Notice of General Meeting
London, UK - 24 April 2023: genedrive plc (LSE: GDR), the point
of care molecular diagnostics company, announces that further to
the announcement on 31 March 2023 confirming that it had agreed
terms on an Equity Prepayment Facility for up to GBP5 million, a
Circular will shortly be published on the Company's website,
www.genedriveplc.com, and will be posted to Shareholders later
today.
The Circular contains the notice convening the General Meeting
to be held at 11.00 a.m. on 11 May 2023 at which resolutions will
be proposed to authorise the allotment of new ordinary shares and
the disapplication of pre-emption rights.
For further information, please contact:
genedrive plc +44 (0) 161 989 0245
David Budd (Chief Executive Officer)
Russ Shaw (Chief Financial Officer)
Peel Hunt LLP - Nominated Adviser, Joint
Broker +44 (0) 20 7148 8900
James Steel / Oliver Duckworth
finnCap Ltd - Joint Broker +44 (0) 20 7220 0500
Geoff Nash / George Dollemore
Walbrook PR - Financial PR & IR
Adviser +44 (0) 20 7933 8780
Paul McManus / Anna Dunphy Or Genedrive@walbrookpr.com
About genedrive plc ( http://www.genedriveplc.com )
genedrive plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and
robust point of need molecular diagnostics platform for the
diagnosis of infectious diseases and for use in patient
stratification (genotyping), pathogen detection and other
indications. The company are currently developing a genetic test
for CYP2C19 metaboliser status.
The Genedrive(R) MT-RNR1 ID Kit, selected as 1 of the 10 EVA
pilot projects, is the world's first commercial point-of-care
genetic test for emergency care. It helps to avoid irreversible
lifelong hearing loss in specific infants exposed to
aminoglycosides by rapidly detecting the m.1555A>G gene variant
that can cause lifelong deafness, allowing for alternative
antibiotics to be prescribed. Product information can be found at
https://www.genedrive.com/assays/rnr1-product.php
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOGSEEFSLEDSEIL
(END) Dow Jones Newswires
April 24, 2023 06:54 ET (10:54 GMT)
Genedrive (LSE:GDR)
Historical Stock Chart
From Apr 2024 to May 2024
Genedrive (LSE:GDR)
Historical Stock Chart
From May 2023 to May 2024